Axatilimab to treat skin thickening (sclerosis) from chronic graft‑versus‑host disease

Axatilimab for Sclerotic Chronic Graft-Versus-Host Disease

This trial tests whether axatilimab can improve or stop worsening skin thickening (sclerosis) in adults with chronic graft‑versus‑host disease after a donor stem cell transplant.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Fred Hutchinson Cancer Center (Academic / other)
• Drugs / interventions: axatilimab, chemotherapy, prednisone
• Locations: 3 sites (Tampa, Florida and 2 other locations)
• Trial ID: NCT07011810 on ClinicalTrials.gov

What this trial studies

This is a phase II interventional trial giving axatilimab by IV infusion to adults with sclerotic chronic graft‑versus‑host disease. Dosing is given over 30 minutes on days 1 and 15 of cycles 1–6 and then on day 1 of subsequent 28‑day cycles for up to 24 cycles unless the disease progresses or toxicity occurs. Participants will have blood samples collected throughout the study and may opt into skin biopsies and skin flexibility assessments to track response. After finishing treatment, patients are followed 30 days later and then for up to two years for safety and longer‑term outcomes.

Who should consider this trial

Good fit: Adults (≥18) who had an allogeneic stem cell transplant and now have active sclerotic cGVHD causing skin thickening diagnosed within the past 24 weeks, requiring systemic treatment, and meeting the trial's sclerotic skin score or PROM thresholds are the intended participants.

Not a fit: Patients without sclerotic skin involvement, those with longstanding sclerosis outside the 24‑week diagnosis window, or people with contraindications to immunomodulatory therapy may be unlikely to benefit from this treatment.

Why it matters

Potential benefit: If successful, axatilimab could reduce skin hardening and improve mobility and quality of life for people with sclerotic cGVHD.

How similar studies have performed: Other targeted immune therapies have shown benefit in cGVHD, but using axatilimab's specific receptor‑blocking approach for sclerosis is relatively novel and less tested.

Eligibility criteria

Inclusion Criteria:

* Adults aged 18 and older
* Ability to understand and willingness to sign a written informed consent document
* Allogeneic stem cell transplant, with active cGVHD requiring systemic treatment. Active cGVHD is defined as the presence of signs and symptoms of cGVHD diagnosed per the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical trials in cGVHD
* Sclerotic skin score 2-3 or PROM \< 24 due to cGVHD
* Initial diagnosis of sclerosis within the past 24 weeks (168 days)
* No new non-corticosteroid systemic immunosuppressive agent within 28 days prior to screening, unless there is a plan to stop them no later than 21 days after the first dose of axatilimab. Receipt of systemic corticosteroids ≤ 1 mg/kg prednisone or prednisone equivalent daily is allowed at the time of enrollment and may be continued after axatilimab initiation
* If patient has been previously treated with systemic immunosuppression for sclerosis, one of the following two conditions must be true: (a) the systemic immunosuppressive treatment(s) were given for at least 60 days and the sclerotic cGVHD either did not respond or progressed; (b) the systemic immunosuppressive treatment(s) were given for less than 60 days due to lack of sclerotic cGVHD response, sclerotic cGVHD progression, toxicity or logistic reasons and have or will be stopped no later than 21 days after the first dose of axatilimab
* Karnofsky performance status ≥ 60%
* Absolute neutrophil count ≥ 1.0 x 10\^9/L (evaluated during the 28-day screening period)
* Platelet count ≥ 50 x 10\^9/L (evaluated during the 28-day screening period) (without transfusion within 2 weeks of study entry)
* If no suspected or proven liver cGVHD, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN) (evaluated during the 28-day screening period) unless due to Gilbert's disease
* If no suspected or proven liver cGVHD, total bilirubin ≤ 1.5 x ULN (evaluated during the 28-day screening period) unless due to Gilbert's disease
* For patients with suspected or documented liver cGVHD, ALT and AST ≤ 5 x ULN (evaluated during the 28-day screening period) unless due to Gilbert's disease
* For patients with suspected or documented liver cGVHD, total bilirubin ≤ 1.5 x ULN (evaluated during the 28-day screening period) unless due to Gilbert's disease
* Estimated creatinine clearance ≥ 30 mL/min based on the institutional formula
* Male and female participants of reproductive potential must be willing to employ highly effective and acceptable forms of contraception from screening through 90 days after the last dose of study treatment.

  * Adolescent and adult male patients capable of fathering a child who are non-sterilized and who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use two methods of birth control from the time of screening throughout the total duration of the study intervention treatment period and 90 days after the last dose of study intervention. Male patients should refrain from sperm donation throughout this period
  * Female patients of childbearing potential who are not abstinent and intend to be sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening throughout the total duration of the study intervention treatment period and 90 days after the last dose of study intervention. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female patients should also refrain from breastfeeding throughout this period
  * Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to treatment initiation. Females of childbearing potential are defined as sexually mature females without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, females who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression

Exclusion Criteria:

* Hospitalization for evaluation or management of an infection within 28 days prior to screening
* History or other evidence of significant organ dysfunction that would make the patient, in the opinion of the investigator, unsuitable for the study
* On more than 1 mg/kg/day prednisone or prednisone equivalent
* History of non-compliance
* History or other evidence of uncontrolled psychiatric illness that that would limit compliance with study requirements
* Receipt of an investigational agent within 28 days prior to screening
* Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening
* Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of study enrollment, unless previously treated with curative intent (e.g. complete resected basal or squamous cell carcinoma of the skin)
* Active hepatitis B (defined as hepatitis B virus \[HBV\] surface antigen positive and HBV core antibody positive, with positive HBV deoxyribonucleic acid \[DNA\], or HBV positive core antibody alone with positive HBV DNA) or hepatitis C (defined as positive hepatitis C \[HCV\] antibody with positive HCV ribonucleic acid \[RNA\])
* Suspected active or latent tuberculosis (as confirmed by a positive QuantiFERON® test or other tuberculosis blood test)
* History of acute or chronic pancreatitis
* History of myositis
* Pregnant or breastfeeding
* Previous exposure to colony stimulating factor 1 receptor (CSF-1R) therapies

Where this trial is running

Tampa, Florida and 2 other locations

• Moffitt Cancer Center — Tampa, Florida, United States (Not_yet_recruiting)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Not_yet_recruiting)
• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (Recruiting)

Study contacts

• Principal investigator: Stephanie J. Lee, MD, MPH — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: cGVHD Intake Coordinator

Conditions Chronic Graft Versus Host Disease